title: Effect of memantine on overactive detrusor in rats with spinal cord injury.
abstract: The aim of this study was to determine the effect of memantine on overactive detrusor (OAD) 15 days after spinal cord injury (SCI) in rats. Twenty-eight adult Wistar rats were used in this study. Fourteen animals served as normal controls, while 14 underwent spinal cord transection (clip compression technique) at the 10th thoracic vertebra. Fifteen days after SCI, all animals underwent urodynamic testing to confirm OAD. Memantine (16 mg/kg) was injected intraperitoneally into rats with SCI and OAD. Parameters measured included voiding volume, micturition pressure, resting bladder pressure, the period between micturitions and the maximum pressure of the OAD during the filling period. Results have showed that OAD developed in 8/14 animals (57.1%). OAD was resolved in 5/8 (62.5%) of these animals after memantine administration. Resting bladder pressure was significantly different in dependent groups (p < 0.05). Micturition pressure increased after SCI but decreased in rats with SCI after memantine injection. However, the period between micturitions was prolonged in both SCI and memantine groups, compared with normal rats. These results show that memantine could be useful for treating neurogenic OAD after SCI by modulating the micturition reflex pathway. Memantine may also provide an alternative treatment option for OAD in the future.
authors.affiliation: Urology Department, Kocaeli University Medical Faculty, Umuttepe, Kocaeli, Turkey. cuneyd65@yahoo.com
authors.forename: Cüneyd
authors.initials: C
authors.lastname: Ozkürkçügil
authors.forename: Osman
authors.initials: O
authors.lastname: Kömür
authors.forename: Levend
authors.initials: L
authors.lastname: Ozkan
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D008559:Memantine / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013119:Spinal Cord Injuries / Q000150:complications*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology
chemical_list: D008559:Memantine
references.citation: J Urol. 2004 Apr;171(4):1709-14
references.pmid: 15017271
references.citation: Eur Urol. 2002 Jan;41(1):6-14
references.pmid: 11999467
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:691-721
references.pmid: 11264473
references.citation: Annu Rev Pharmacol Toxicol. 1989;29:365-402
references.pmid: 2543272
references.citation: Urology. 1999 Nov;54(5):929-33
references.pmid: 10565763
references.citation: Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S47-54
references.pmid: 12973750
references.citation: Neurosci Lett. 1995 Jan 2;183(1-2):58-61
references.pmid: 7746488
references.citation: Brain Res Brain Res Protoc. 2002 Feb;9(1):57-64
references.pmid: 11852271
references.citation: Epilepsy Res. 1993 Oct;16(2):165-74
references.pmid: 8269915
references.citation: Neuropharmacology. 1993 Dec;32(12):1337-50
references.pmid: 8152525
references.citation: Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32
references.pmid: 12973747
references.citation: Prog Neurobiol. 1999 Oct;59(3):279-98
references.pmid: 10465381
references.citation: Neurourol Urodyn. 2000;19(1):87-99
references.pmid: 10602250
references.citation: Annu Rev Gerontol Geriatr. 1989;9:232-79
references.pmid: 2514767
references.citation: Eur J Pharmacol. 1995 Dec 4;287(1):73-8
references.pmid: 8666029
references.citation: J Pharmacol Exp Ther. 2002 Feb;300(2):421-7
references.pmid: 11805200
references.citation: Urology. 2002 May;59(5 Suppl 1):18-24
references.pmid: 12007518
references.citation: Behav Pharmacol. 2005 May;16(3):155-61
references.pmid: 15864070
references.citation: Neurourol Urodyn. 2002;21(2):167-78
references.pmid: 11857671